Loading clinical trials...
Loading clinical trials...
The study will evaluate the antipsychotic efficacy of QLM1016 in a multicenter, randomized, double-blind, parallel controlled study in patients diagnosed with schizophrenia.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
NCT07565428 · Negative Symptoms of Schizophrenia
NCT07645443 · Early Onset Psychosis, First Psychotic Episode Within the Last 5 Years, and more
NCT06257056 · Treatment-Refractory Schizophrenia
NCT07288333 · Schizophrenia
NCT07105098 · Schizophrenia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions